

Best Therapeutic Food Products Developer - Nordics

Based in the dynamic Medicon Valley Region of Malmö, Sweden, ColoPlus AB is a research and development company founded by highly respected specialists from Lund University Hospital. The organisation is dedicated to developing therapeutic nutraceutical food products that contain antibodies and growth factors derived from bovine colostrum. Through several studies, ColoPlus has demonstrated the efficacy of its product, ColoPlus IMCARE, in treating HIV-related diarrhea and increasing immunity.

Colostrum is a fluid secreted by all mammals in the first few days of lactation after parturition. When secreted by cows, this liquid is referred to as bovine colostrum, which is rich in protein and nutrients beneficial for growth and immunity. It also contains protease inhibitors which prevents it from being degraded by digestion processes.

ColoPlus has established a protocol to collect colostrum within 24 hours from parturition. In this way, the company facilitates higher returns for the first cow milk, which otherwise would have gone to waste. The quality of the colostrum is crucial for the therapeutic effects of the product, so it is handled with great care during industrial processing to prevent a distortion of the liquid's naturally balanced proportions.

Through this, the company brings its customers one of the most potent food products available today, ColoPlus IMCARE. Its formulation contains an extensive list of vitamins and minerals, immunoglobulins, and essential amino acids, all contributing to good health and immune system strengthening. The product is consumed orally, so these immunoglobulins remain in the digestive tract, attacking disease-causing organisms that enter the body through food and water. ColoPlus IMCARE also prevents bacteria from attaching to the intestinal wall, effectively preventing intestinal infections. These qualities make the product ideal for individuals with suppressed immune systems caused by medical conditions like cancer and HIV.

ColoPlus IMCARE is a dry porridge powder which combines two components, a bioactive factor (bovine colostrum) and a vehicle made of organic particulate matter. The product is easy to prepare by mixing water into porridge. Consuming ColoPlus IMCARE with porridge prolongs the transit of its bioactive ingredients through the gastrointestinal tract, minimising degradation and maximising exposure for antimicrobial action and nutritional absorption. Additional benefits of the consumption in porridge form include

its suitability for people of all ages, religions, and health states, as well as the provision of macronutrients like carbohydrates. Additionally, the powder does not require refrigeration, making it convenient to store.

The benefits of ColoPlus IMCARE are clinically proven, backed by studies that have qualified for publication in recognised medical journals. In a 2006 Scandinavian Journal of Gastroenterology study, ColoPlus treated 30 patients with HIV-associated diarrhoea at the Braithwaite Memorial Specialist Hospital in Nigeria. After four weeks of treatment with ColoPlus, stool evacuations per day were found to be dramatically decreased, self-estimated fatigue reduced, and body weight increased. This suggests that ColoPlus offers an important alternative or additional treatment for HIV-associated diarrhea. To measure the product's effect on immunity, CD4+ white blood cells were measured. This study observed a 125% increase in CD4+ cell count, demonstrating its potential to strengthen compromised immune systems.

In a later study in 2008 which took place in Uganda, the effects of ColoPlus IMCARE on patients with HIV-associated diarrhea were tested again, this time in comparison with a control group of patients only receiving routine anti-diarrhea treatment. In the ColoPlus patients, there was an 83% decrease in daily stool frequency, whereas control patients experienced only a 60% decrease. The ColoPlus patients reached average stool frequency in 7 days, whereas the progress was much slower for control patients, taking about 21 days to achieve normal stool frequency. Self-estimated fatigue was reduced by 85% for patients on ColoPlus compared to 43% for controls during the study period. Patients on ColoPlus were more likely to gain weight than those who did not receive ColoPlus, and there was a 14% increase in the mean CD4+ cell count in patients on ColoPlus in contrast with a 12% decrease in the controls. This study demonstrates the product's efficacy in treating diarrhea and strengthening the immune system.

Later, ColoPlus investigated the effects of its product on the nutritional status and immunological capacity of malnourished HIV-infected children. For four weeks, 50 grams of ColoPlus IMCARE was administered to 850 HIV-positive children in selected health facilities in Northern Uganda. Of these children, 48 were recruited and observed for 12 weeks. Treatment with ColoPlus resulted in a general improvement in the children's well-being, with their body weight increasing and fatigue decreasing. All the children tolerated ColoPlus well, and no side effects were observed. In the more extended study of 48 children, CD4+ cells were measured across 12 weeks. In the fourth week after their treatment with ColoPlus, there was an increase in CD4+ values in comparison with the first week. By the eighth week, this had decreased somewhat, then returned to 0 values by week 12. Haemoglobin and serum albumin showed a similar trend. This study effectively demonstrated the product's suitability for children. It showed that the positive effects were prolonged and remained for at least four weeks after the treatment stopped, making it a cost-effective method of increasing immunity.



Thanks to its innovative product, with extensive research backing its positive effects, ColoPlus AB has won Best Therapeutic Food Products Developer, Nordics, in the Biotechnology Awards 2023. The company continues to carry out ground-breaking research and development within the biotechnology industry, aiming to

utilize bovine colostrum to help improve health and immunity in people worldwide.

Company: ColoPlus AB
Web Address: <https://www.coloplus.se/>

GHP Biotechnology Awards 2023